ClinicalThought
The New Array of Choices in Prostate Cancer—What’s Best for Your Patients?
Release Date: January 12, 2022
Expiration Date: January 11, 2023
Not certified for credit.
Begin »
Program Overview
Program Description
A range of available and emerging therapeutic agents across the continuum of prostate cancer offer new options for healthcare providers and their patients. This commentary offers an overview of current treatment strategies and best approaches in diagnosis, treatment, and adverse event management to provide optimal outcomes for patients with prostate cancer.
Format
Clinical Thought
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Rana R. McKay, MD
- Associate Professor
- Department of Medicine
- Divisions of Hematology/Oncology and Urology
- University of California San Diego
- San Diego, California
Details
This activity is supported by educational grants from Astellas and Bayer HealthCare Pharmaceuticals Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Dr McKay: consulting fees: AstraZeneca, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novarits, Sanofi, Sorrento Therapeutics; Vividion Therapeutics; consulting fees/contracted research: Bayer, Pfizer, Tempus.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 103421GUBC-CTP